U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C6H11NO2
Molecular Weight 129.1573
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VIGABATRIN

SMILES

C=CC(CCC(=O)O)N

InChI

InChIKey=PJDFLNIOAUIZSL-UHFFFAOYSA-N
InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22061175

Vigabatrin is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin prevents the catabolism of GABA by irreversibly inhibiting the enzyme GABA transaminase. It is an analog of GABA, but it is not a receptor agonist. However, vigabatrin is not a potent inhibitor of GABA-T with a Ki of 10 mM. Vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase, GABA-T). Duration of action is determined by rate of GABA-T re-synthesis. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. Vigabatrin is sold under the trade name SABRIL, it is indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SABRIL

Approved Use

SABRIL is an antiepileptic drug (AED) indicated for: • Refractory Complex Partial Seizures in Adults (1.1). It should be used as adjunctive therapy in patients who have responded inadequately to several alternative treatments.

Launch Date

1.25072638E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.4 μg/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
73 μg × h/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Disc. AE: Sedation, Seizures...
Other AEs: Weight gain, Depression...
AEs leading to
discontinuation/dose reduction:
Sedation (9%)
Seizures (2%)
Status epilepticus (1%)
Other AEs:
Weight gain (6%)
Depression (1%)
Excitability (1%)
Itching (1%)
Headache (1%)
Irritability (1%)
Muscle pain (1%)
Libido decreased (1%)
Sources: Page: p.745
2 g 2 times / day multiple, oral
Highest studied dose
Dose: 2 g, 2 times / day
Route: oral
Route: multiple
Dose: 2 g, 2 times / day
Sources: Page: p.460
healthy, 25.8 ± 8.2
n = 24
Health Status: healthy
Age Group: 25.8 ± 8.2
Sex: M
Population Size: 24
Sources: Page: p.460
4 g single, oral
Highest studied dose
Dose: 4 g
Route: oral
Route: single
Dose: 4 g
Sources: Page: p.460
healthy, 27.0 ± 8.2
n = 24
Health Status: healthy
Age Group: 27.0 ± 8.2
Sex: M
Population Size: 24
Sources: Page: p.460
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources: Page: p.81
unhealthy, 35 ± 11
n = 41
Health Status: unhealthy
Condition: Complex Partial Seizures
Age Group: 35 ± 11
Sex: M+F
Population Size: 41
Sources: Page: p.81
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Other AEs: Coma, Unconsciousness...
Other AEs:
Coma (common)
Unconsciousness (common)
Drowsiness (common)
Vertigo (uncommon)
Psychosis (uncommon)
Apnea (uncommon)
Respiratory depression (uncommon)
Bradycardia (uncommon)
Agitation (uncommon)
Irritability (uncommon)
Confusion (uncommon)
Headache (uncommon)
Hypotension (uncommon)
Abnormal behavior (uncommon)
Seizures (uncommon)
Status epilepticus (uncommon)
Speech disorder (uncommon)
Sources: Page: p.16
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Other AEs: Vision loss, Brain MRI signal changes...
Other AEs:
Vision loss
Brain MRI signal changes
Suicidal behavior
Suicidal ideation
Anemia
Somnolence
Fatigue
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Depression 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Excitability 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Headache 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Irritability 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Itching 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Libido decreased 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Muscle pain 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Status epilepticus 1%
Disc. AE
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Seizures 2%
Disc. AE
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Weight gain 6%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Sedation 9%
Disc. AE
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources: Page: p.745
unhealthy, 16-63
n = 99
Health Status: unhealthy
Condition: Epilepsy
Age Group: 16-63
Sex: M+F
Population Size: 99
Sources: Page: p.745
Coma common
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Drowsiness common
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Unconsciousness common
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Abnormal behavior uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Agitation uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Apnea uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Bradycardia uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Confusion uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Headache uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Hypotension uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Irritability uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Psychosis uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Respiratory depression uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Seizures uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Speech disorder uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Status epilepticus uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Vertigo uncommon
90 g single, oral (max)
Overdose
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.16
Anemia
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Brain MRI signal changes
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Fatigue
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Somnolence
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Suicidal behavior
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Suicidal ideation
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Vision loss
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Refractory Complex Partial Seizures
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
weak (co-administration study)
Comment: A 16% to 20% average reduction in total phenytoin plasma levels was reported (see label page 21)
Page: 70.0
likely
weak (co-administration study)
Comment: A 16% to 20% average reduction in total phenytoin plasma levels was reported (see label page 21)
Page: 70.0
no
no (co-administration study)
Comment: No significant difference in pharmacokinetic parameters of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel; vigabatrin did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested
Page: 22.0
no
no (co-administration study)
Comment: No significant difference in pharmacokinetic parameters of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel; vigabatrin did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested
Page: 22.0
not significant
not significant
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
A risk-benefit assessment of treatments for infantile spasms.
2001
Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.
2001
The management of refractory idiopathic epilepsies.
2001
Management strategies for refractory localization-related seizures.
2001
Epileptic encephalopathy.
2001
GABAergic mechanisms in epilepsy.
2001
The new generation of GABA enhancers. Potential in the treatment of epilepsy.
2001
Visual field defects with vigabatrin: epidemiology and therapeutic implications.
2001
Behavioural effects of the new anticonvulsants.
2001
Effects of antiepileptic drugs on cognition.
2001
Visual field defects and other ophthalmological disturbances associated with vigabatrin.
2001
The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy.
2001
Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
2001 Apr
The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.
2001 Apr
GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter.
2001 Apr 15
Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance.
2001 Aug
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
Paradoxical reduction of synaptic inhibition by vigabatrin.
2001 Aug
Vigabatrin effect on inner retinal function.
2001 Aug
Effects of radiofrequency exposure on the GABAergic system in the rat cerebellum: clues from semi-quantitative immunohistochemistry.
2001 Aug 31
[Antiepileptic drugs and neuropathic pain].
2001 Feb 16-28
Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
2001 Jan
[Vigabatrin and visual fields defects].
2001 Jan 8
Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers.
2001 Jan-Feb
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?
2001 Jul
Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy.
2001 Jul 1
Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina.
2001 Jul 24
Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.
2001 Jul-Aug
[Reversible phenytoin-induced extrapontine myelinolysis].
2001 Jun
Visual field loss associated with vigabatrin: pathological correlations.
2001 Jun
Placental transfer of vigabatrin (gamma-vinyl GABA) and its effect on concentration of amino acids in the embryo of TO mice.
2001 Mar
[Social and economic aspects of administration of new antiepileptic drugs].
2001 Mar-Apr
[Vigabatrin-induced cytolytic hepatitis].
2001 May
Vigabatrin visual toxicity: evolution and dose dependence.
2001 May
Gamma-vinyl GABA reduces paired pulse inhibition in the rat dentate gyrus in vivo and in vitro.
2001 May
[Therapeutic strategy in severe encephalopathies].
2001 May 1-15
National survey on West syndrome in Korea.
2001 Nov
What is West syndrome?
2001 Nov
Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
2001 Nov
Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy.
2001 Nov
Infantile spasms: diagnosis and assessment of treatment response by video-EEG.
2001 Oct
Anxiolytic effects of vigabatrin in panic disorder.
2001 Oct
Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase.
2001 Oct
Single systemic dose of vigabatrin induces early proconvulsant and later anticonvulsant effect in rats.
2001 Oct 12
Randomized trial of vigabatrin in patients with infantile spasms.
2001 Oct 23
Plasticity of rat central inhibitory synapses through GABA metabolism.
2001 Sep 1
Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats.
2001 Sep 1
Decrease in GABA synthesis rate in rat cortex following GABA-transaminase inhibition correlates with the decrease in GAD(67) protein.
2001 Sep 28
Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
2001 Sep 5
Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine.
2002 Jan 1
Patents

Patents

Sample Use Guides

Refractory Complex Partial Seizures Adults >16 years of age: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1500 mg twice daily (2.2). Pediatrics 10 to 16 years of age: Treatment is based on body weight. Initiate therapy at 250 mg twice daily, increasing total daily dose per instructions. The recommended maintenance dose is 1000 mg twice daily. Patients weighing more than 60 kg should be dosed according to adult recommendations (2.2). Infantile Spasms Initiate therapy at 50 mg/kg/day given in 2 divided doses increasing total daily dose per instructions to a maximum of 150 mg/kg/day given in 2 divided doses (2.3). Given orally with or without food.
Route of Administration: Oral
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34 ± 3 and 53 ± 2%, respectively, at a concentration of 30 mM.
Name Type Language
VIGABATRIN
DASH   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
4-AMINO-5-HEXENOIC ACID
Systematic Name English
GAMMA-VINYL GABA
Common Name English
VIGABATRIN [INN]
Common Name English
VIGABATRIN [USP MONOGRAPH]
Common Name English
VINYL GAMMA-AMINOBUTYRIC ACID
Systematic Name English
VIGABATRIN [USAN]
Common Name English
VIGABATRIN [ORANGE BOOK]
Common Name English
VIGABATRIN, (+/-)-
Common Name English
VIGABATRIN [MART.]
Common Name English
VIGABATRIN [EP MONOGRAPH]
Common Name English
VIGABATRIN [JAN]
Common Name English
5-HEXENOIC ACID, 4-AMINO-
Common Name English
MDL 71,754
Code English
RMI-71754
Code English
SABRIL
Brand Name English
VIGABATRIN [WHO-DD]
Common Name English
CPP-109
Code English
GAMMA VINYL GABA
Common Name English
VIGABATRIN [USP-RS]
Common Name English
MDL-71754
Code English
VIGABATRIN [VANDF]
Common Name English
VIGABATRIN [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 609817
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
NCI_THESAURUS C264
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
FDA ORPHAN DRUG 135100
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
WHO-ATC N03AG04
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
LIVERTOX 1027
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
NDF-RT N0000175753
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
WHO-VATC QN03AG04
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
Code System Code Type Description
PUBCHEM
5665
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
RXCUI
14851
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB01080
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
MESH
D020888
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
LACTMED
Vigabatrin
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
WIKIPEDIA
VIGABATRIN
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
FDA UNII
GR120KRT6K
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
NCI_THESAURUS
C87611
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
EVMPD
SUB00048MIG
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
CAS
60643-86-9
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
SUPERSEDED
INN
5581
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
IUPHAR
4821
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
DRUG CENTRAL
2819
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
MERCK INDEX
M11445
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY Merck Index
CAS
68506-86-5
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL89598
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY
USP_CATALOG
1712001
Created by admin on Fri Jun 25 20:33:20 UTC 2021 , Edited by admin on Fri Jun 25 20:33:20 UTC 2021
PRIMARY USP-RS